PSMA-targeted imaging of prostate cancer： evolution of a success story  

作　　者：Tobias Maurer Matthias Eiber 

机构地区：[1]Department of Urology, .Techn.ical University of Muni.ch, Munich: Germany [2]Department of Nuclear Medicine, Technical University of Munich, Munich, Germany [3]Department of Molecular and Medical Pharmacology, David Geflen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

出　　处：《Asian Journal of Andrology》2017年第3期388-388,共1页亚洲男性学杂志（英文版）

摘　　要：Management of prostate cancer patients with biochemical relapse has long hampered due to insufficient capability to detect and localize recurrent disease with available imaging modalities such as CT, MRI, or bone scintigraphy. Recent advances in functional imaging, namely, PET and SPEGT imaging, with novel tracers targeting the prostate-specific membrane antigen （PSMA） have led to a surge in imaging in prostate cancer patients with biochemical relapse since was able to reveal sites of recurrence in a claritv not seen before.Management of prostate cancer patients with biochemical relapse has long hampered due to insufficient capability to detect and localize recurrent disease with available imaging modalities such as CT, MRI, or bone scintigraphy. Recent advances in functional imaging, namely, PET and SPEGT imaging, with novel tracers targeting the prostate-specific membrane antigen （PSMA） have led to a surge in imaging in prostate cancer patients with biochemical relapse since was able to reveal sites of recurrence in a claritv not seen before.

分 类 号：R[医药卫生]